Compare Macy's Inc (M) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs Pfizer Inc — how do they compare? Macy's Inc trades at $22.38 (market cap $5.95B), while Pfizer Inc trades at $28.01 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 26.6× Macy's Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Macy's Inc for 58 Days and Pfizer Inc for 158 Days on average.
| M | PFE | |
|---|---|---|
Market Cap | $5.95B | $158.56B |
Volume | 6,030,644 | 44,138,282 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.21 | $29.02 |
52-Week Low | $16.51 | $23.67 |
Typical Hold Time | 58 Days | 158 Days |
Enterprise Value | $9.75B | $210.06B |
Dividend Yield | 3.36% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's (M) trades at $22.79, up 1.47% today, with a bullish technical signal from moving averages. The stock shows attractive valuation with a P/E of 8.35 and P/S of 0.27. Recent earnings have consistently beaten estimates, and the company's 'Bold New Chapter' strategy is driving digital and omnichannel growth, though revenue has trended down from $25.3B in 2022 to $23.0B in 2025.
The outlook is mixed; strong cash flow and a 3.5% dividend yield support income investors, but competitive pressures and uneven growth pose risks. Analyst consensus is a $24.25 price target with a Hold bias. Execution of the turnaround strategy remains key to unlocking value amid retail sector challenges.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
